Impressive results with The Histotype Px Colorectal cancer marker published in The Lancet Oncology

Oslo, Norway - DoMore Diagnostics, a pioneer in developing prognostic and predictive cancer markers in digital pathology, today announced that a new study documenting the Histotype Px Colorectal has been published in The Lancet Oncology. The study shows that Histotype Px Colorectal algorithm predicts patient outcomes even more accurately when used in combination with tumor and lymph node status.

Figure 1:

Proposed risk stratification system for patients with stage II or III colorectal cancer judged to have no residual tumour (R0) by the end of the surgical procedure.

The algorithm is previously observed to outperform established molecular and morphological markers of patient outcome after primary colorectal cancer resection with a Hazard Ratio of 3,84 for patients with poor outcome versus good outcome (Lancet 2020; 395: 350–60). This new article documents an even stronger marker when addition of tumor and lymph node status and dividing patients into low, intermediate and high risk. The high-risk patients versus low-risk patients had a Hazard Ratio of 10,71.

Figure 2: : Kaplan-Meier curves of cancer-specific survival for the validation dataset by the proposed or the guideline-based risk stratification system

All patients were evaluated by the proposed risk stratification system for the primary analysis.

The researchers in the study concludes that integrating the algorithm and pathological staging markers provides a clinical decision support system that risk stratifies more accurately than its constituent elements, and identifies substantially more patients with stage II and III colorectal cancer with similarly good prognosis as the low-risk group in current guidelines, and that avoiding adjuvant chemotherapy in these patients might be safe, and could reduce morbidity, mortality, and treatment costs.

Every year close to 2 million patients worldwide are diagnosed with colorectal cancer, and despite decades of comprehensive research and large investments into gene sequencing, there is large medical need for better prognostic and predictive markers for patients with colorectal cancer. Many of these patients will suffer from unnecessary and harmful overtreatment while others may receive less intensive treatment than they need. This new data shows that the Histotype Px Colorectal can provide distinctive patient risk information. The marker is also available to clinicians and patients immediately after surgery, weeks to months faster than markers available today.

“This is a very important milestone for the DoMore Diagnostics. We are extremely pleased to see the strength of the Histotype Px Colorectal when combined with status of the tumor and lymph nodes. A hazard ratio above 10 between high and low risk patients is impressive. The data are certainly very important for the Histotype Px Colorectal product, but it also is a validation of our technology and approach to stratify patients in meaningful risk groups”, DoMore Diagnostics CEO and Co-founder Torbjørn Furuseth.

Click here to go to the article at The Lancet Oncology